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Abstract
Background: Myocarditis is an inflammation of the myocardium that often follows the enterovirus infections, with
coxsackievirus B3 (CVB3) being the most dominant etiologic agent. We and other groups previously reported that
chemokine IP-10 was significantly induced in the heart tissue of CVB3-infected mice and contributed to the migration of
massive inflammatory cells into the myocardium, which represents one of the most important mechanisms of viral
myocarditis. To evaluate the direct effect of IP-10 on the inflammatory responses in CVB3 myocarditis, herein an IP-10
mutant deprived of chemo-attractant function was introduced into mice to antagonize the endogenous IP-10 activity, and
its therapeutic effect on CVB3-induced myocarditis was evaluated.
Methodology/Principal Findings: The depletion mutant pIP-10-AT, with an additional methionine after removal of the 5 N-
terminal amino acids, was genetically constructed and intramuscularly injected into BALB/c mice after CVB3 infection.
Compared with vector or no treatment, pIP-10-AT treatment had significantly reduced heart/body weight ratio and serum
CK-MB level, increased survival rate and improved heart histopathology, suggesting an ameliorated myocarditis. This
therapeutic effect was not attributable to an enhanced viral clearance, but to a blunted Th1 immune response, as evidenced
by significantly decreased splenic CD4
+/CD8
+IFN-c
+ T cell percentages and reduced myocardial Th1 cytokine levels.
Conclusion/Significance: Our findings constitute the first preclinical data indicating that interfering in vivo IP-10 activity
could ameliorate CVB3 induced myocarditis. This strategy may represent as a new therapeutic approach in treating viral
myocarditis.
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Introduction
Viral myocarditis represents a leading cause of sudden death in
young adults. Up to 20% of patients with histological evidence of
myocarditis will ultimately develop dilated cardiomyopathy, a fatal
disease leaving heart transplantation as the only treatment [1–3].
Enteroviruses of the picornavirus family are considered to be the
dominant etiology of viral myocarditis, with coxsackievirus B3
(CVB3) being the most common one. The murine model of
CVB3-induced myocarditis has been developed that shares many
characteristics with human disease. Despite decades of extensive
effort, the pathogenesis of viral myocarditis is still not fully
understood. Studies in the murine CVB3 myocarditis model have
found that although CVB3 can directly destroy myocardium, the
strong host Th1 immune responses may play a more critical
pathogenetic role in the course of viral myocarditis, verified by the
improvement of heart injury and function by immune modulating
and inhibiting agents [4–6].
During CVB3 infection, massive myocardial immune cell
inflammation could be observed in the mouse model [7]. This
process of immune cell trafficking and infiltration is mainly
controlled by chemokines and their receptors. It has been proved
that MCP-1 [8], MIP-1b and MIP-3b [9] are involved in the
cardiac-directed migration of mononuclear cells in viral myocardi-
tis. Beside of their chemo-attractant function, chemokines are also
known for their properties to modulate the direction and strength of
immune responses including cell activation and differentiation, thus
to influence the severity and prognosis of inflammatory heart
diseases [10–12]. It indicates that chemokines might be a potential
target of molecular therapy for viral myocarditis.
Recently, we and other groups reported that expression of CXC
chemokine interferon-inducible protein 10 (IP-10) was induced in the
heart tissue during CVB3 infection and may play a role in the
initiation and progression of myocardial inflammation [13–15].
Through its receptor CXCR3, IP-10 robustly attracts activated NK
and T cells to infection sites to eliminate invaded pathogens [16,17],
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as a Th1-type chemokine, IP-10 preferentially promotes Th1 immune
responses which have been proved to be detrimental to viral
myocarditis [18]. Therefore, we speculate that IP-10 may have dual
effects (protective versus immune pathologic) on the CVB3-induced
myocarditis. Herein we hypothesize that blocking endogenous IP-10
activity after CVB3 infection may counteract its chemotactic activity
and compromise the excessive pathological injury in the heart tissue
mediated by viral induced Th1 immune responses.
A mutant IP-10, designated as IP-10-AT, with a methionine
added following the removal of the 5 N-terminal amino acids, was
genetically constructed. It was designed to antagonize the chemo-
attractant effect of endogenous IP-10 by competitively binding to
CXCR3 receptor [19]. Injection of pIP-10-AT plasmid via
intramuscular route has shown the efficient expression in vivo and
the obvious blocking effect on IP-10 activity in remote target organs
[19]. In the present study, pIP-10-AT was intramuscularly injected
into BALB/c mice after CVB3 infection, and its therapeutic
efficiency against CVB3-induced myocarditis was evaluated.
Results
CVB3 infection up-regulates the cardiac IP-10 expression
in a time- and dose-dependent manner
To understand whether IP-10 play a role in CVB3-induced
myocarditis, the kinetic expression of IP-10 following CVB3
infection was first observed. BALB/c mice were infected with 10
3
TCID50 dose of CVB3 for various time periods or with different
CVB3 doses for 4 days, the heart tissues were collected,
homogenized and then subjected to ELISA assays. As shown in
Fig. 1A, hardly any cardiac IP-10 could be detected before virus
infection. However, after CVB3 infection, slightly up-regulated IP-
10 expression was observed as early as 1 day post-infection, and
achieved the maximum at day 4, with significantly higher IP-10
level (8.62 ng/ml) than that of day 0 (p,0.05). IP-10 expression
could be induced by CVB3 at a dose as low as 10 TCID50 and
correspondingly augmented as CVB3 dose increased (Fig. 1B).
These results indicated that IP-10 expression was induced robustly
by CVB3 infection in a time- and dose-dependent manner.
Construction, expression and chemotaxis-antagonizing
function of pIP-10-AT
To antagonize the chemotaxic effect of endogenous IP-10, a
mutant IP-10 plasmid designated as pIP-10-AT lacking the 5 N-
terminal amino acids was constructed. Native IP-10 protein
exhibits the classical chemokine fold, a three-stranded b-sheet
overlaid by a a-helix, and is stabilized by disulfide bonds between
two pairs of conserved N-terminal cysteines (Fig. 2A). After
depleting the chemo-attractant essential part of IP-10 (highlighted
in yellow), a methionine and a 66His tag were respectively added
to the N- and C-terminuses of the truncated protein to form the
mutant IP-10-AT (Fig. 2B and C).
To verify the transcriptional efficiency of plasmids in vitro,a
lipofectamine-aided transfection assay was conducted on 293T
cells, then IP-10-AT and IP-10 expressions in supernatants were
analyzed by sandwich ELISA assays. As shown in Fig. 2D, similar
expressions of IP-10-AT (590 pg/ml) and IP-10 (540 pg/ml) were
detected at 48 h post-transfection. Next, the chemotaxis-antago-
nizing ability of IP-10-AT was evaluated in vitro and in vivo. It was
found that expressed IP-10-AT protein was deprived of the
chemotaxis function towards immune cells in vitro (Fig. 3A). And
when administrated together, mononuclear cells infiltration in
pIP-10 injected muscles could be robustly abrogated by pIP-10-
AT co-injection (Fig. 3C and D). These data indicated that IP-10-
AT mutant could be efficiently expressed and antagonize the IP-
10-mediated immune cell recruitment in vitro and in vivo. The
competitive binding ability of IP-10-AT with IP-10 to the receptor
CXCR3 was also detected. As shown in Fig. 3B, a distinct
decrease of fluorescence intensity of CHO/mCXCR3 cells was
observed when FITC-IP-10 was added with unlabeled IP-10-AT
protein. The higher concentration of IP-10-AT, the lower
fluorescence intensity was seen, indicating that IP-10-AT compet-
itively inhibited the binding of FITC-IP-10 to CXCR3 on CHO
cells. No such shift of fluorescence intensity was observed with the
addition of unlabeled BSA.
Treatment with pIP-10-AT protects mice from CVB3-
induced myocarditis
To assess the therapeutic effect of IP-10-AT mutant on CVB3
myocarditis, mice were infected with 10
3 TCID50 CVB3, and then
intramuscularly injected with 2 dose of 100 mg pIP-10-AT at day 0
and 3. The survival rate and body weight were monitored. As
shown in Fig. 4A and B, mice with no or pcDNA3.1 treatment
underwent a dramatic and continuous loss of body weight as
maximal to 20%, and more than 70% mice died within 14 days
post-infection. On the contrary, mice receiving pIP-10-AT had a
little fluctuation in body weight and a significantly improved
survival rate (66.7%). Consistent with that, serological indices of
Figure 1. Expression kinetics of IP-10 in the heart tissue following CVB3 infection. (A) BALB/c mice were infected with 10
3 TCID50 dose of
CVB3, and the expression level of IP-10 in heart tissue was detected by ELISA assays at different time points. (B) Expression level of IP-10 in heart
tissue was detected at day 4 following different doses of CVB3 infection. The results were presented as the mean 6SD of three separate experiments.
*, p,0.05.
doi:10.1371/journal.pone.0018186.g001
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pIP-10-AT treatment compared with pcDNA3.1- or non-treated
mice (Fig. 4C and D), indicating a significantly reduced
myocardial injury.
To see the situation of heart tissue, pIP-10-AT treatment led to
a significantly reduced heart/body weight ratio compared with
control groups (5.3560.51 vs. 7.3160.30, 7.3660.30 mg/g,
p,0.05) (Fig. 4E). Significantly improved histopathology of heart
tissue, evidenced by fewer inflammation and limited necrosis
lesions (Fig. 4F and H), was also observed indicating the
ameliorated myocarditis. Consistently, nearly complete destruc-
tions of pancreas were showed in control mice on day 8 post-
infection, while there was only minimal to mild inflammation or
little damage was seen in pIP-10-AT treated mice (Fig. 4H).
Theses protective effects were not due to the alteration of cardiac
or pancreatic viral load as evidenced by PFU assay (Fig. 4G).
Reduced Th1 immune responses by pIP-10-AT treatment
CVB3-induced excessive Th1 immune responses were proved
to play an important role in the initiation and progression of
CVB3 myocarditis. To investigate the immune-modulation
mechanism of pIP-10-AT, splenic IFN-c
+ or IL-4
+ T cell
frequencies and heart Th1/Th2 cytokine profiles were respectively
evaluated by FACS and ELISA on day 8 following CVB3
infection. As shown in Fig. 5A, 3.79% of CD4
+IFN-c
+ and 3.85%
CD8
+IFN-c
+ T cells were evidenced in pIP-10-AT-treated mice,
significantly lower than those of pcDNA3.1-treated mice
(CD4
+IFN-c
+ T cells: 5.27%; CD8
+IFN-c
+ T cells: 6.01%,
p,0.05). While, percentages of CD4
+/CD8
+ IL-4
+ T cells did
not showed remarkable differences between these two groups.
Similarly, the levels of cardiac Th1 cytokines (IFN-c, IL-12, TNF-
a) were extensively and dramatically decreased in pIP-10-AT
treated mice compared with other groups. As high as 960 pg/ml
of IFN-c and 1150 pg/ml of TNF-a were reduced to lower levels
(510 pg/ml and 330 pg/ml). In contrast, hardly changed Th2
cytokine expressions were noticed except of the slight down-
regulation of IL-13, indicating that pIP-10-AT treatment effi-
ciently impaired Th1 immune responses by significantly reducing
Th1 cytokine production, which may ameliorate the CVB3-
induced myocardial injury.
Discussion
Viral myocarditis is an inflammation of the myocardium that
follows enterovirus or adenovirus infections. It is the composite
result of both virus infection and host uncontrolled immune
reactions [20]. During the early viremia period, CVB3 infects
heart tissues by receptor-mediated endocytosis [21] and may cause
myocardiocyte dysfunction by disrupting dystrophin-sarcoglycan
complex or cleaving eukaryotic initiation factor-4 [22]. At later
stage of infection, proinflammatory cytokines and chemokines are
robustly expressed and result in the massive inflammation and
aggravated injury in heart [23]. Our previous study demonstrated
that cardiac MCP-1, a Th1 chemokine, was obviously up-
regulated in vivo and in vitro following CVB3 infection and was
one of the leading causes of the cardiac inflammation and immune
injury [8]. Other reports indicate that the expression pattern, level
and kinetics of cytokines, chemokines and their receptors are
closely related to the progress and severity of inflammatory heart
diseases [24–27]. Therefore to re-establish an immune balance by
modulating chemokine and cytokine expressions represents as a
potential therapeutic strategy for viral myocarditis.
Figure 2. Construction and expression of pIP-10-AT. (A) Structure of IP-10 protein. a, Ribbon diagram of IP-10 monomer (Protein Data Bank
number 2R3Z). b, Space filled model of IP-10 in the same orientation as a. Basic residues were highlighted in pink. N-terminal residues 1–5 were
critical residues for chemotaxis and highlighted in yellow. (B) Schematic representation of plasmids encoding IP-10 and IP-10-AT. (C) Structure of IP-
10-AT protein. a, Ribbon diagram of IP-10-AT. b, Space filled model of IP-10-AT in the same orientation as a. Basic residues lacking the first 5 N-
terminal amino acids were highlighted in pink and an additonal methionine was highlighted in green. (D) Expression of pIP-10-AT in vitro. 293T cells
were transfected with the indicated plasmids, and 48 h later cell supernatant was collected and subjected to ELISA assay. The results were presented
as the mean 6SD of three separate experiments.
doi:10.1371/journal.pone.0018186.g002
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heart tissue following CVB3 infection [13,28]. We confirmed this
phenomenon in this study and for the first time extensively
described the expression kinetics of cardiac IP-10 in CVB3
infected mice. We found that IP-10 was induced as early as day 1
post-infection, peaked at day 4, and then slightly decayed and
maintained a high level until day 7, appearing in a time-dependent
manner. This expression pattern was coincident with the kinetic
changes of cardiac CVB3 titers, which also peaked at day 3–4 and
then gradually subsided [29]. Meanwhile, the cardiac IP-10
expression also increased in parallel with the virus dose. These
consistencies reflect the intimate interaction and communication
between host immunity and CVB3 virus, and may indicate that
the IP-10 induction is the host essential immune response for
CVB3 infection. Weinzierl AO et al [13] reported the benefit role
of IP-10 at the initial stage of CVB3 infection using IP-10
2/2 mice
model. Yuan J et al [28] recently demonstrated that IP-10 helped
to inhibit viral replication at the early stage of CVB3 myocarditis
(at day 3 post-infection). However, at the climax of acute infection
(day 7 to 10 post-infection), neither over-expression nor deficiency
of IP-10 could significantly alter the viral clearance, myocarditis
severity or mouse survival rate, suggesting an early and temporal
virus-limiting effect and a complex role of IP-10 in the course of
CVB3 myocarditis.
It is well-established that in the sub-acute stage of CVB3
myocarditis (day 4–14), excessive immune responses become the
dominant damage factor instead of virus virulence [30]. Th1-
dominant immunity has been considered as one of the important
Figure 3. Analysis of the chemotactic and chemotaxis-antagonizing effects of pIP-10-AT. (A) Chemotactic effect of pIP-10-AT in vitro. 293T
cells were transfected with the indicated plasmids; 48 h later cell supernatant was collected and subjected to chemotaxis assays. (B) Competitive
binding assay. CHO/mCXCR3 cells were incubated with FITC-IP-10 protein (20 mg/ml) and unlabeled competitor IP-10-AT protein (200-600 mg/ml).
Unlabeled BSA was used as a negative control. Cells were washed extensively to remove unbound protein and analyzed by flow cytometry. Mean
fluorescence intensities (MFI) are plotted as a function of increasing quantities of competitor proteins. Error bars represent three independent
experiments. (C) Chemotactic and antagnizing effects of pIP-10-AT in vivo. Muscular sections at the injection sites were prepared 3 days after pIP-10
or pIP-10-AT intramuscular injection. (D) Recruited cell number in muscular tissues of mice receiving indicated plasmids. The results were presented
as the mean 6SD of three separate experiments.
doi:10.1371/journal.pone.0018186.g003
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shift of Th1 to Th2 immune response could alleviate the
myocarditis severity [31]. IP-10 is considered as a Th1-type
chemokine and plays a critical role in many Th1-mediated
diseases, such as colitis [32], sarcoidosis [33], inflammatory lung
injury [34] and visceral leishmaniasis [35]. Thus, blocking IP-10/
CXCR3 signaling pathway may significantly impair the induction
and recruitment of Th1 cells to local tissue site, weaken the
secondary tissue injury and improve organ functions.
In this study, a plasmid encoding mutant IP-10 (pIP-10-AT),
which antagonize IP-10-mediated cell chemotaxis by competitively
binding CXCR3 receptor (Fig. 3B), was used to treat mice after
CVB3 infection. We found that pIP-10-AT injection significantly
improved the pancreas injury as well as myocarditis manifestations
including serum indices and myocardial histopathology. These
protective roles were not due to the control of viral replication
since no decline of cardiac or pancreatic viral titer was evidenced,
but rather partially resulted from the efficient blockade of the
inflammatory cell trafficking into tissues, as demonstrated in
Figs. 3C and 4H. Blocking endogenous IP-10 also led to a
significant rectification of Th1 dominant immune responses,
evidenced by decreased frequencies of splenic CD4
+IFN-c
+ and
CD8
+IFN-c
+ T cells, reduced cardiac Th1 cytokine levels (IFN-c,
IL-12 and TNF-a), and hardly no decreased Th2 cytokine
expressions except of IL-13. IL-13 has been shown to exert
protective effects against CVB3 myocarditis by suppressing
proinflammatory cytokine production and down-regulating T-cell
immune responses [36]. The inconsistency between the decreased
protective IL-13 and the improved myocarditis by pIP-10-AT
might be explained by an overwhelming beneficial effect of Th1
cytokine reduction to a relevant weak detrimental effect of solely
Th2 cytokine (IL-13) decrease.
In conclusion, we report for the first time the protective effect
of IP-10 blocking strategy in treating CVB3-induced myocarditis,
and demonstrate the pIP-10-AT injection as an effective means to
antagonize endogenous IP-10 function, and thus suppress
chemokine-directed immune inflammation and resultant myo-
cardial injury, when therapy was applied after the onset of
disease. This IP-10-antagonism strategy may provide an alterna-
tive therapeutic approach in the future treatment of viral
myocarditis and possible other Th1-mediated inflammatory heart
diseases.
Figure 5. The systemic and local Th1/Th2 immune responses after pIP-10-AT treatment. Mice were infected with 10
3 TCID50 dose of CVB3
and received 2 doses of 100 mg of pIP-10-AT or pcDNA3.1 by intramuscular injection on day 0 and day 3. At day 8, splenocytes (2610
6/ml) were
isolated and reactivated in vitro with 10 mg/ml of plate-bound anti-CD3 and 2 mg/ml soluble anti-CD28 antibody for 24 h. For the final 4 h, 1 mg/ml of
GolgiStop was added. Cells were harvested and stained with FITC-conjugated anti-mouse CD4 or anti-mouse CD8. After washing, cells were fixed,
permeabilized and then stained with PE-conjugated anti-mouse IFN-c or anti-mouse IL-4. The percentage of IFN-c- or IL-4-secreting CD4
+ (A) or CD8
+
(B) T cells were analyzed by flow cytometry. Meanwhile, the heart tissues were homogenized, the expression levels of Th1 (C) and Th2 (D) cytokines
were determined by ELISA assays. Each group contains 6 mice.
doi:10.1371/journal.pone.0018186.g005
Figure 4. pIP-10-AT administration ameliorates CVB3-induced myocarditis. Mice were infected with 10
3 TCID50 dose of CVB3 and
administrated intramuscularly with 2 doses of pIP-10-AT or pcDNA3.1 at day 0 and 3. The body weight change (A) and survival rate (B) were
respectively monitored daily until day 7 and day 14 post-infection. Meanwhile, serological indices of myocarditis, the activity of TnI (C) and level of
CK-MB (D) in mouse serum were also detected on day 8 post-infection. (E) The ratio of heart weight to body weight was evaluated. (F) Paraffin
sections of heart tissues were prepared and cardiac inflammation was revealed by HE staining. The severity of myocarditis was scored by a standard
0–4 scale according to the foci of mononuclear infiltration and myocardial necrosis. *, p,0.05. (G) Viral loads in the heart and pancreas tissues on day
8 post-infection were determined by plaque assay on Hela cells. *, p,0.05; N.D., not detected. (H) Representative heart and pancreas sections were
shown for each group, magnification 6200.
doi:10.1371/journal.pone.0018186.g004
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Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Medical
Laboratory Animals (Ministry of Health, P. R. China, 1998). The
protocol was approved by the Medical Laboratory Animal Care
and Use Committee of Jiangsu Province (Permit Number: SYXK
2007-0035) as well as the Ethical Committee of Soochow
University (Permit Number: 2007011).
Mice and virus
Male inbred BALB/c (H-2
d) mice 6–8 weeks of age were
purchased from the Experimental Animal Center of Chinese
Academy of Science (Shanghai, P. R. China). CVB3 (Nancy
strain) was a gift from Professor Yingzhen Yang (Key Laboratory
of Viral Heart Diseases, Zhongshan Hospital, Shanghai Medical
college of Fudan University) and was maintained by passage
through Hela cells (ATCC number: CCL-2). Viral titer was
routinely determined prior to infection by a 50% tissue culture
infectious dose (TCID50) assay of Hela cell monolayer.
Cardiac IP-10 ELISA assay
Freshly isolated heart tissues were ground to a fine powder
under liquid nitrogen. Each sample (100 mg of powdered tissue)
was homogenized in 0.5 ml RIPA buffer and subsequently
centrifuged in a cooled micro-centrifuge for 8 min. The
supernatants were then subjected to ELISA assays with mouse
IP-10 construction ELISA kits (Antigenix America Inc).
Construction of pIP-10-AT plasmid
Plasmid encoding murine IP-10 (pIP-10) has been constructed
previously [37]. The IP-10-AT (AT: antagonist) gene with a
66His tag at the C-terminal was yielded by method of gene
splicing to add a methionine after removal of the first 5 N-terminal
amino acids. Following confirmation of the entire nucleotide
sequence, the fragment was then incorporated into the eukaryotic
expression plasmid pcDNA3.1.
Expression of pIP-10-AT plasmid
Human embryonic kidney 293T cells (ATCC CRL-11268) were
transfected with pIP-10 or pIP-10-AT by lipofectamine (Invitro-
gen) and cultured for 48 h. The supernatants of transfected cells
were collected and subjected to mouse IP-10 quantitative ELISA
assay according to manufacturer’s instructions (Antigenix America
Inc).
Chemotaxis assays in vitro and in vivo
The chemotaxis assay in vitro was conducted using a modified
48-well Boyden chamber migration assay. Concanavalin A (ConA)
activated splenocytes were transferred to upper chambers (1610
5
cells/50 ml). The supernatant from pIP-10-AT or pIP-10 trans-
fected 293T cells was pretreated with anti-IP-10 (10 mg/ml) or
isotype antibody before adding to the lower chamber. IP-10
protein prepared by ourselves was used as a positive control. After
4 h incubation, migration was expressed as cell number per five
high-power fields in the polycarbonate chemotaxis membrane,
with duplicate wells being counted for each of three experiments.
The chemotaxis ability of pIP-10 or pIP-10-AT was evaluated by
the chemotactic index [(number of cells migrating in experimental
well)/(number of cells migrating in medium well)].
The chemotaxis assay in vivo was conducted as follows: mice
were injected with 100 mg pIP-10-AT, 100 mg pIP-10, 100 mg pIP-
10-AT plus 100 mg pIP-10 or 100 mg pcDNA3.1 at the sites of
femoral muscle. 3 days later, the muscle tissues were fixed in 10%
buffered formalin, sectioned and stained with hematoxylin and
eosin (HE). Sections were observed using a Nikon Eclipse TE2000-
S microscope with magnification 6200, and evaluated for the
blockade effect of pIP-10-AT on pIP-10-mediated chamotaxis.
Competitive binding assay
The competitive binding ability of IP-10-AT with IP-10 to their
receptor CXCR3 was detected as described previously [38].
Recombinant IP-10 and IP-10-AT proteins were expressed in E.
coli and then purified by the methods discribed previously [39].
Mouse CXCR3 stable-transfected CHO cells (ATCC CCL-61,
4610
5) were incubated with FITC-labeled IP-10 (20 mg/ml) with
or without unlabeled IP-10-AT or BSA (200–600 mg/ml) for
1 hour at 4uC and washed extensively to remove unbound protein,
and analyzed by flow cytometry.
CVB3 infection and pIP-10-AT therapy
Mice were intraperitoneally infected with 10
3 TCID50 CVB3 at
day 0, and then immediately received intramuscular injection of
100 mg pIP-10-AT twice at day 0 and day 3. Mice receiving
pcDNA3.1 were used as a negative control group.
Tissue histopathology and myocarditis grading
8 days following CVB3 infection, heart and pancreas tissues of
mice were collected, sectioned and subjected to HE staining. Heart
sections were examined by two independent investigators in a
blinded manner, and the severity of myocarditis was assessed by a
previously described 0–4 scale [40], in which 0= no inflamma-
tion; 1= one to five distinct mononuclear inflammatory foci with
involvement of 5% or less of the cross-sectional area; 2= more
than five distinct mononuclear inflammatory foci, or involvement
of over 5% but not over 20% of the cross-sectional area; 3=
diffuse mononuclear inflammation involving over 20% of the area,
without necrosis; and 4= diffuse inflammation with necrosis.
Intracellular staining
8 days following CVB3 infection, splenocytes (2610
6/ml) were
isolated and reactivated in vitro with 10 mg/ml of plate-bound anti-
CD3 (eBioscience) and 2 mg/ml soluble anti-CD28 antibody
(eBioscience) for 24 h. For the final 4 h, 1 mg/ml of GolgiStop (BD
Pharmingen) was added. Cells were harvested and stained with
FITC-conjugated anti-mouse CD4 or anti-mouse CD8 antibody
(eBioscience), after washing the cells were fixed with fixation buffer
(eBioscience) for 20 min at 4uC and permeabilized with permea-
bilization solution (eBioscience) for 20 min at room temperature,
and then stained with PE-conjugated anti-mouse IFN-c or anti-
mouse IL-4 (eBioscience). The percentage of cytokine-secreting
CD4
+ or CD8
+T cells was determined by flow cytometry using a
FACScalibur instrument (Becton Dickinson).
Cytokine ELISA
Expressions of IFN-c, IL-12, TNF-a, IL-4, IL-10 and IL-13 in
the homogenized heart tissues were measured by ELISA assays
(R&D, except IL-13 ELISA kit from eBioscience) following the
manufacturers’ instructions. In brief, plates were coated with
diluted capture antibody (100 ml/well) and incubated overnight at
4uC. Samples and standards were added to triplicate wells and
incubated at 37uC for 2 h. After washing, biotinylated detection
antibody was added for 1 h, followed by 100 ml strepavidin
conjugated horseradish peroxidase for 1 h at 37uC. TMB substrate
(eBioscience) was added to each well. After 10 min, 50 ml of stop
CVB3-Myocarditis Amelioration by IP-10 Therapy
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450 nm.
Quantization of tissue viral load
8 days after 10
3 TCID50 CVB3 infections, heart and pancreas
tissues were collected, weighed and frozen at -70uC in 10% FBS-
RPMI 1640 medium. Samples were later thawed, homogenized,
serially diluted in 10-fold increments, and incubated on confluent
Hela cell monolayer for 1 h at 37uC and 5% CO2 to allow virus
attachment, and then incubated for 7 days to allow plaque
formation. Viral titer was expressed as the mean PFU/100 mg
tissue 6 SD.
Statistical analysis
Data are shown as the mean 6 SD. Statistical analysis of the
data was performed using the GraphPad Prism (Version 4.0)
statistical program. Means were compared using the Student’s
two-sample t-test. The survival rates of CVB3 infected mice were
compared and analyzed with Kaplan-Meier plot. p,0.05 was
considered statistically significant.
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